SARS‐CoV‐2‐specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID‐19 vaccination. Issue 7 (28th April 2022)

• Record Type: Journal Article
• Authors: Jarisch, Andrea; Wiercinska, Eliza; Daqiq‐Mirdad, Shabnam; Hellstern, Helen; Ajib, Salem; Cremer, Anjali; Nguyen, Ngoc Thien Thu; Dukat, Alexandra; Ullrich, Evelyn; Ciesek, Sandra; Chow, Kai‐Uwe; Serve, Hubert; Seifried, Erhard; Bader, Peter; Bonig, Halvard; Bug, Gesine
• Is Part Of: European journal of immunology. Volume 52:Issue 7(2022)
• Page Start: 1194
• Page End: 1197
• Publication Date: 2022-04-28
• Subjects: HSCT -- SARS‐CoV‐2 -- SARS‐CoV‐2‐specific T cells -- vaccination; Immunology -- Periodicals; 616.079
• DOI: 10.1002/eji.202149771
• Languages: English
• ISSNs: 0014-2980

Abstract

Abstract : Little is known about the cellular immune response to SARS‐CoV‐2 vaccination in patients after HSCT and B‐NHL with iatrogenic B‐cell aplasia. In nonseroconverted HSCT patients, induction of specific T‐cell responses was assessed. The majority of allogeneic HSCT patients not showing humoral responses to vaccination also fail to mount antigen‐specific T‐cell responses.